Total Payments
$1.7M
2024 Payments
$356,192
Companies
38
Transactions
1,774
Medicare Patients
1,602
Medicare Billing
$295,169
Payment Breakdown by Category
Other$854,458 (48.8%)
Consulting$540,334 (30.9%)
Travel$247,460 (14.1%)
Research$58,148 (3.3%)
Food & Beverage$49,173 (2.8%)
Education$190.82 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $799,456 | 272 | 45.7% |
| Consulting Fee | $540,334 | 138 | 30.9% |
| Travel and Lodging | $247,460 | 457 | 14.1% |
| Unspecified | $58,148 | 118 | 3.3% |
| Honoraria | $53,350 | 23 | 3.0% |
| Food and Beverage | $49,173 | 755 | 2.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $950.00 | 1 | 0.1% |
| Grant | $701.32 | 1 | 0.0% |
| Education | $190.82 | 9 | 0.0% |
Payments by Type
General
$1.7M
1,656 transactions
Research
$58,148
118 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $373,725 | 241 | $0 (2024) |
| Optinose US, Inc. | $333,504 | 384 | $0 (2024) |
| GENZYME CORPORATION | $295,542 | 211 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $278,960 | 225 | $0 (2024) |
| Medtronic USA, Inc. | $78,504 | 86 | $0 (2020) |
| AERIN MEDICAL INC. | $65,183 | 51 | $0 (2024) |
| Medtronic, Inc. | $57,996 | 97 | $0 (2024) |
| ALK-Abello, Inc | $35,426 | 43 | $0 (2022) |
| Intersect ENT, Inc. | $32,306 | 93 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $29,071 | 45 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $356,192 | 275 | GlaxoSmithKline, LLC. ($126,744) |
| 2023 | $283,828 | 251 | GlaxoSmithKline, LLC. ($114,563) |
| 2022 | $261,451 | 285 | OptiNose US, Inc. ($70,444) |
| 2021 | $259,794 | 228 | Optinose US, Inc. ($82,403) |
| 2020 | $131,387 | 135 | Regeneron Healthcare Solutions, Inc. ($31,697) |
| 2019 | $255,474 | 309 | Regeneron Healthcare Solutions, Inc. ($63,163) |
| 2018 | $110,612 | 181 | GENZYME CORPORATION ($38,028) |
| 2017 | $91,026 | 110 | Medtronic USA, Inc. ($21,787) |
All Payment Transactions
1,774 individual payment records from CMS Open Payments — Page 1 of 71
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $268.50 | General |
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $227.36 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $287.06 | General |
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $228.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids • Category: Immunology | ||||||
| 12/04/2024 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $837.00 | General |
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $268.50 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | In-kind items and services | $957.07 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $388.95 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $268.50 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $253.09 | General |
| 11/21/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $6,400.00 | General |
| 11/21/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $1,600.00 | General |
| 11/21/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $1,600.00 | General |
| 11/21/2024 | AERIN MEDICAL INC. | VIVAER STYLUS (Device), RHINAER STYLUS | Food and Beverage | In-kind items and services | $238.15 | General |
| Category: EAR NOSE & THROAT | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $115.72 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $106.67 | General |
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.15 | General |
| 11/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $98.74 | General |
| 11/09/2024 | AERIN MEDICAL INC. | VIVAER STYLUS (Device), RHINAER STYLUS | Food and Beverage | In-kind items and services | $185.25 | General |
| Category: EAR NOSE & THROAT | ||||||
| 11/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $65.27 | General |
| 11/09/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $37.23 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | Cash or cash equivalent | $162.01 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | Cash or cash equivalent | $22.96 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intra | SANOFI-AVENTIS U.S. LLC | $14,607 | 36 |
| A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS, A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | F. Hoffmann-La Roche AG | $13,943 | 12 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $10,500 | 21 |
| A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $4,500 | 9 |
| ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | Regeneron Pharmaceuticals, Inc. | $2,559 | 5 |
| A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids | GENZYME CORPORATION | $2,500 | 2 |
| A PhIII RANDOMIZED TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS and PH3 RANDOMIZED MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF OMALIZUMAB FOR NASAL POLYPS | F. Hoffmann-La Roche AG | $2,384 | 2 |
| A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T | GlaxoSmithKline, LLC. | $1,610 | 11 |
| Insmed BIRCH Study | Insmed, Inc. | $1,387 | 4 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | SANOFI-AVENTIS U.S. LLC | $1,250 | 1 |
| A RANDOMISED PHIII STUDY TO ASSESS THE EFFECT OF 100 MG SC MEPOLIZUMAB | GlaxoSmithKline, LLC. | $1,109 | 10 |
| A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of duplilumab 300 mg every other week, in patients with bilaternal nasap polyposis on a background therapy with intranasal corticosteroids | SANOFI-AVENTIS U.S. LLC | $907.55 | 2 |
| A randomized, double-blind, 52-week, placebo controlled efficacy and safety study of dupilumab, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids | GENZYME CORPORATION | $750.00 | 2 |
| A randomized, 24-week treatment, double-blind, placebo-controlled efficacy and safety study of dupilumab 300 mg every other week, in patients with bilateral nasal polyposis on a background therapy w | SANOFI-AVENTIS U.S. LLC | $142.04 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 414 | 555 | $267,440 | $78,555 |
| 2022 | 9 | 386 | 488 | $171,570 | $63,281 |
| 2021 | 9 | 388 | 512 | $206,800 | $75,225 |
| 2020 | 12 | 414 | 734 | $267,305 | $78,108 |
Total Patients
1,602
Total Services
2,289
Medicare Billing
$295,169
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2023 | 135 | 224 | $97,615 | $31,985 | 32.8% |
| 31237 | Biopsy or removal of nasal polyp or tissue using an endoscope | Office | 2023 | 30 | 44 | $44,255 | $11,136 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 93 | 122 | $17,080 | $7,751 | 45.4% |
| 31276 | Exploration of nasal sinus using an endoscope | Facility | 2023 | 17 | 17 | $32,335 | $6,885 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 58 | $12,180 | $5,385 | 44.2% |
| 31255 | Removal of nasal sinus using an endoscope | Facility | 2023 | 15 | 15 | $19,665 | $4,014 | 20.4% |
| 61782 | Computer-assisted procedure outside membrane covering brain | Facility | 2023 | 25 | 25 | $9,535 | $3,351 | 35.1% |
| 31267 | Removal of nasal sinus tissue using an endoscope | Facility | 2023 | 16 | 16 | $18,295 | $3,293 | 18.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $7,360 | $2,903 | 39.4% |
| 31288 | Removal of sphenoid nasal sinus tissue using an endoscope | Facility | 2023 | 11 | 11 | $9,120 | $1,851 | 20.3% |
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2022 | 149 | 219 | $89,790 | $32,553 | 36.3% |
| 31237 | Biopsy or removal of nasal polyp or tissue using an endoscope | Office | 2022 | 19 | 29 | $26,445 | $7,640 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 74 | $15,540 | $6,450 | 41.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 61 | 70 | $9,800 | $4,919 | 50.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $10,240 | $3,865 | 37.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 25 | $7,000 | $3,263 | 46.6% |
| 61782 | Computer-assisted procedure outside membrane covering brain | Facility | 2022 | 15 | 15 | $5,625 | $2,096 | 37.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $4,400 | $1,558 | 35.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $2,730 | $936.30 | 34.3% |
| 31231 | Diagnostic examination of nasal passages using an endoscope | Office | 2021 | 146 | 220 | $90,200 | $34,583 | 38.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 81 | 109 | $22,890 | $11,116 | 48.6% |
| 31237 | Biopsy or removal of nasal polyp or tissue using an endoscope | Office | 2021 | 18 | 32 | $33,210 | $8,610 | 25.9% |
| 31276 | Exploration of nasal sinus using an endoscope | Facility | 2021 | 11 | 11 | $22,575 | $4,565 | 20.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 35 | 35 | $11,200 | $4,549 | 40.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 24 | 28 | $7,840 | $3,756 | 47.9% |
About Dr. Joseph Han, MD
Dr. Joseph Han, MD is a Otolaryngology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760577985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Han, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $356,192 received in 2024. These payments were reported across 1,774 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($799,456).
As a Medicare-enrolled provider, Han has provided services to 1,602 Medicare beneficiaries, totaling 2,289 services with total Medicare billing of $295,169. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Otolaryngology
- Other Specialties Pediatric Otolaryngology, Facial Plastic Surgery
- Location Norfolk, VA
- Active Since 10/04/2006
- Last Updated 07/31/2015
- Taxonomy Code 207Y00000X
- Entity Type Individual
- NPI Number 1760577985
Products in Payments
- DUPIXENT (Biological) $464,605
- Xhance (Drug) $333,504
- NUCALA (Biological) $180,506
- DUPIXENT (Drug) $69,788
- VIVAER STYLUS (Device) $57,585
- NUVENT (Device) $42,728
- Xolair (Biological) $33,471
- FASENRA (Drug) $27,601
- NO PRODUCT DISCUSSED (Drug) $23,190
- Odactra (Drug) $21,160
- STRAIGHTSHOT (Device) $19,913
- PROPEL (Device) $18,336
- DUPIXENT DUPILUMAB INJECTION (Biological) $16,848
- FUSION (Device) $10,742
- FASENRA (Biological) $8,763
- STEALTHSTATION S8 PLATFORM (Device) $7,864
- Dymista (Drug) $6,723
- RHINAER STYLUS (Device) $5,923
- AIRSUPRA (Drug) $5,719
- StealthStation (Device) $5,117
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Otolaryngology Doctors in Norfolk
Dr. Kent Lam, M.d, M.D
Otolaryngology — Payments: $116,796
Otolaryngology $116,796
Craig Derkay, M.d, M.D
Otolaryngology — Payments: $15,621
Otolaryngology $15,621
David Darrow, M.d, M.D
Otolaryngology — Payments: $12,869
Otolaryngology $12,869
Dr. Stephanie Moody Antonio, Md, MD
Otolaryngology — Payments: $3,894
Otolaryngology $3,894
John Kalafsky, M.d, M.D
Otolaryngology — Payments: $3,230
Otolaryngology $3,230
Dr. Ashley Schroeder, Md, MD
Otolaryngology — Payments: $1,856
Otolaryngology $1,856